【私募调研记录】呈瑞投资调研博瑞医药

Group 1 - The core viewpoint is that Chengrui Investment has conducted research on the listed company Borui Pharmaceutical, focusing on the collaboration with China Resources Sanjiu to commercialize the BGM0504 product in China [1] - Borui Pharmaceutical's BGM0504 product is expected to demonstrate its advantages through more clinical trials, and it has global competitiveness with plans for international expansion [1] - The BGM1812 product is characterized by fat reduction without muscle loss and is currently advancing IND applications in both China and the US [1] Group 2 - Chengrui Investment, established in May 2010, has a registered capital of 11 million and has been recognized for its stable development in the secondary market and various investment strategies [2] - The company has a professional research team of 33 members, with backgrounds from prestigious universities, and has received multiple industry awards for its performance [2] - Chengrui Investment has diversified its client base, which includes banks, private banks, securities firms, insurance companies, trusts, and various institutional investors [2]